Zai Lab
Yajing Chen join Zai Lab in September 2021 as Deputy Chief Financial Officer.
Ms. Chen, a seasoned finance executive and leader with more than 20 years life sciences industry experience, oversees all aspects of finance, accounting, tax, treasury, procurement, and IT. She is recognized for her deep business acumen spanning R&D, sales, marketing, market access and operations. She is skilled at building strategy, establishing new processes, developing teams, and delivering on challenging goals.
Prior to joining Zai Lab, she served as Chief Financial Officer for AstraZeneca’s (AZ) U.S Oncology Business Unit. At AZ, she led the 10-year strategic plan and contributed to the enormous growth of AZ’s global oncology business. As a PhD-trained scientist, Yajing brings a unique combination of scientific know-how, finance domain expertise and business acumen to her position.
Ms. Chen holds a Ph.D. in Microbiology from New York University and an MBA from Columbia University.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.